Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - Reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations

BMC Neurology

Volumn 6, Issue , 2006, Pages

  Then Berg, Florian ^a,d   Kümpfel, Tania ^a,e   Schumann, Erina ^a   Held, Ulrike ^b   Schwan, Michaela ^a   Blazevic, Mirjana ^c   Wismüller, Axel ^c   Holsboer, Florian ^a   Yassouridis, Alexander ^a   Uhr, Manfred ^a   Weber, Frank ^a   Daumer, Martin ^b   Trenkwalder, Claudia ^a,f   Auer, Dorothee P ^a,g  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Sylvia Lawry Centre for Multiple Sclerosis Research   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f Paracelsus Klinik   (Germany)

^g UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; DEXAMETHASONE; GADOLINIUM; HYDROCORTISONE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; PROLACTIN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BONE DENSITY; BRAIN DAMAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN TEST; CROSSOVER PROCEDURE; DATA ANALYSIS; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; IMAGE ANALYSIS; LABORATORY TEST; MALE; MULTIPLE SCLEROSIS; OPEN STUDY; OUTCOME ASSESSMENT; PROLACTIN BLOOD LEVEL; RANK SUM TEST; RELAPSE; REMISSION; SINGLE DRUG DOSE;

ADULT; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; BRAIN; CROSS-OVER STUDIES; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GADOLINIUM; HORMONES; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROLACTIN; RECEPTORS, CYTOKINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745938938     PISSN: 14712377     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-6-19     Document Type: Article

References (44)

1. Milligan NM, Newcombe R, Compston DA: A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neural Neurosurg Psychiatry 1987, 50:511-6.
2. Thompson AJ, Kennard C, Swash M, Summers B, Yuill GM, Shepherd DI, Roche S, Perkin GD, Loizou LA, Ferner R, Hughes RAC, Thompson M, Hand J: Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989, 39:969-971.
3. Optic Neuritis Study Group: The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 1997, 49:1404-1413.
4. Beck RW, Trobe JD, Moke PS, Gal RL, Xing D, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner JL, Kupersmith MJ, Miller NR, Nazarian S, Orengo-Nania S, Savino PJ, Shults WT, Smith CH, Wall M: High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003, 121:944-949.
5. Kaufman DI, Trobe JD, Eggenberger ER, Whitaker JN: Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:2039-2044.
6. Goodkin DE, Kinkel RP, Weinstock-Guttman B, VanderBrug-Medendorp S, Secic M, Gogol D, Perryman JE, Uccelli MM, Neilley L: A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998, 51:239-45.
7. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M: Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001, 57:1239-1247.
8. Miller DH, Thompson AJ, Morrissey SP, MacManus DG, Moore SG, Kendall BE, Moseley IF, McDonald WI: High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992, 55:450-453.
9. Burnham JA, Wright RR, Dreisbach J, Murray RS: The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 1991, 41:1349-1354.
10. Barkhof F, Hommes OR, Scheltens P, Valk J: Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991, 41:1219-1222.
11. Gold R, Buttgereit F, Toyka KV: Mechanism of action of gluco-corticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 2001, 117:1-8.
12. Webster JI, Tonelli L, Sternberg EM: Neuroendocrine regulation of immunity. Annu Rev Immunol 2002, 20:125-163.
13. Then Bergh F, Kümpfel T, Trenkwalder C, Rupprecht R, Holsboer F: Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. Neurology 1999, 53:772-777.
14. Schumann EM, Kümpfel T, Then Bergh F, Trenkwalder C, Holsboer F, Auer DP: Activity of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: correlations with gadolinium-enhancing lesions and ventricular volume. Ann Neurol 2002, 51:763-767.
15. Michelson D, Stone L, Galliven E, Magiakou MA, Chrousos GP, Sternberg EM, Gold PW: Multiple sclerosis is associated with alterations in hypothalamic-pituitary-adrenal axis function. J Clin Endocrinol Metab 1994, 79:848-853.
16. Kira J, Harada M, Yamaguchi Y, Shida N, Goto I: Hyperprolactinemia in multiple sclerosis. J Neural Sci 1991, 102:61-66.
17. Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, Lublin FD, Paty DW, Reingold SC, Simon J: Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996, 39:6-16.
18. Sormani MP, Miller DH, Comi G, Barkhof F, Rovaris M, Bruzzi P, Filippi M: Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. J Neurol Neurosurg Psychiatry 2001, 70:494-499.
19. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtelotte WW: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 13:227-231.
20. Wismüller A, Behrends J, Lange O, Jukic M, Hahn K, Reiser MF, Auer DP: High-precision computer-assisted segmentation of multispectral data sets in patients with multiple sclerosis by a flexible machine learning image analysis approach. In Bildverarbeitung für die Medizin 2003 Edited by: Wittenberg T. Berlin: Springer Verlag; 2003:403-407.
21. Ge Y, Grossman RI, Udupa JK, Wei L, Mannon LJ, Polansky M, Kolson DL: Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology 2000, 214:665-670.
22. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
23. Barkhof F, Tas M, Frequin ST, Scheltens P, Hommes OR, Nauta JJ, Valk J: Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology 1994, 36:382-387.
24. Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, McFarland HF: The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995, 37:611-619.
25. Waubant E, Goodkin DE, Sloan R, Andersson PB: A pilot study of MRI activity before and during interferon beta- 1a therapy. Neurology 1999, 53:874-876.
26. Filippi M, Rovaris M, Capra R, Gasperini C, Prandini F, Martinelli V, Horsfield MA, Bastianello S, Sormani MP, Pozzilli C, Comi G: Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. J Neurol Neurosurg Psychiatry 1999, 67:386-389.
27. Mancardi GL, Sardanelli F, Parodi RC, Melani E, Capello E, Inglese M, Ferrari A, Sormani MP, Ottonello C, Levrero F, Uccelli A, Bruzzi P. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 1998, 50:1127-1133.
28. Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CR, Weiner HL, Gasperini C, Filippi M: Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999, 353:964-9.
29. Hoogervorst EL, Polman CH, Barkhof F: Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Mult Scler 2002, 8:415-419.
30. Rao AB, Richert N, Howard T, Lewis BK, Bash CN, McFarland HF, Frank JA. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology 2002, 59:688-694.
31. Kesselring J, Miller DH, MacManus DG, Johnson G, Milligan NM, Scolding N, Compston DA, McDonald WI: Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone. J Neurol Neurosurg Psychiatry 1989, 52:14-7.
32. Azar ST, Yamout B: Prolactin secretion is increased in patients with multiple sclerosis. Endocr Res 1999, 25:207-14.
33. Reder AT, Lowy MT. Serum prolactin levels in active multiple sclerosis and during cyclosporin treatment. J Neurol Sci 1993, 117:192-6.
34. Heesen C, Gold SM, Bruhn M, Monch A, Schulz KH: Prolactin stimulation in multiple sclerosis - an indicator of disease subtypes and activity? Endocr Res 2002, 28:9-18.
35. Vera-Lastra O, Jara LJ, Espinoza LR: Prolactin and autoimmunity. Autoimmun Rey 2002, 1:360-364.
36. Koller M, Kotzmann H, Clodi M, Riedl M, Luger A. Effect of elevated serum prolactin concentrations on the immunophenotype of human lymphocytes, mitogen-induced proliferation and phagocytic activity of polymorphonuclear cells. Eur J Clin Invest 1997, 27:662-666.
37. Matera L, Galetto A, Geuna M, Vekemans K, Ricotti E, Contarini M, Moro F, Basso G: Individual and combined effect of granulocyte-macrophage colony-stimulating factor and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions. Immunology 2000, 100-29-36.
38. Perez Castro C, Penalva R, Paez Pereda M, Renner U, Reul JM, Stalla GK, Holsboer F, Arzt E: Early activation of thyrotropin-releasing-hormone and prolactin plays a critical role during a T cell-dependent immune response. Endocrinology 1999, 140:690-697.
39. Krishnan N, Thellin O, Buckley DJ, Horseman ND, Buckley AR: Prolactin suppresses glucocorticoid-induced thymocyte apoptosis in vivo. Endocrinology 2003, 144:2102-2110.
40. Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinal Metab 2000, 85:42-47.
41. Rupprecht M, Rupprecht R, Koch HU, Haack D, Muller OA, Hornstein OP: Multihormonal response to dexamethasone. A study in atopic dermatitis and normal controls. Acta Derm Venereol 1991, 71:214-218.
42. Hubina E, Nagy GM, Toth BE, Ivan G, Gorombey Z, Szabolcs I, Kovacs L, Goth MI: Dexamethasone and adrenocorticotropin suppress prolactin secretion in humans. Endocrine 2002, 18:215-219.
43. Zorzon M, Zivadinov R, Locatelli L, Giuntini D, Toncic M, Bosco A, Nasuelli D, Bratina A, Tommasi MA, Rudick RA, Cazzato G: Longterm effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 2005, 12:550-556.
44. Sylvia Lawry Center for Multiple Sclerosis Research [http://www.slcmsr_net/en/partner/cooperations.html]